Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
OATD-02 Validates the Benefits of Pharmacological Inhibition of Arginase 1 and 2 in Cancer.
Grzybowski MM, Stańczak PS, Pomper P, Błaszczyk R, Borek B, Gzik A, Nowicka J, Jędrzejczak K, Brzezińska J, Rejczak T, Güner-Chalimoniuk NC, Kikulska A, Mlącki M, Pęczkowicz-Szyszka J, Olczak J, Gołębiowski A, Dzwonek K, Dobrzański P, Zasłona Z. Grzybowski MM, et al. Among authors: pomper p. Cancers (Basel). 2022 Aug 17;14(16):3967. doi: 10.3390/cancers14163967. Cancers (Basel). 2022. PMID: 36010962 Free PMC article.
Potent but transient immunosuppression of T-cells is a general feature of CD71+ erythroid cells.
Grzywa TM, Sosnowska A, Rydzynska Z, Lazniewski M, Plewczynski D, Klicka K, Malecka-Gieldowska M, Rodziewicz-Lurzynska A, Ciepiela O, Justyniarska M, Pomper P, Grzybowski MM, Blaszczyk R, Wegrzynowicz M, Tomaszewska A, Basak G, Golab J, Nowis D. Grzywa TM, et al. Among authors: pomper p. Commun Biol. 2021 Dec 10;4(1):1384. doi: 10.1038/s42003-021-02914-4. Commun Biol. 2021. PMID: 34893694 Free PMC article.
Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy.
Borek B, Nowicka J, Gzik A, Dziegielewski M, Jedrzejczak K, Brzezinska J, Grzybowski M, Stanczak P, Pomper P, Zagozdzon A, Rejczak T, Matyszewski K, Golebiowski A, Olczak J, Lisiecki K, Tyszkiewicz M, Kania M, Piasecka S, Cabaj A, Dera P, Mulewski K, Chrzanowski J, Kusmirek D, Sobolewska E, Magdycz M, Mucha L, Masnyk M, Golab J, Nowotny M, Nowak E, Napiorkowska-Gromadzka A, Pikul S, Jazwiec R, Dzwonek K, Dobrzanski P, Meyring M, Skowronek K, Iwanowski P, Zaslona Z, Blaszczyk R. Borek B, et al. Among authors: pomper p. Mol Cancer Ther. 2023 Jul 5;22(7):807-817. doi: 10.1158/1535-7163.MCT-22-0721. Mol Cancer Ther. 2023. PMID: 36939275
Gender-based differences in mortality in response to high product ratio massive transfusion.
Rowell SE, Barbosa RR, Allison CE, Van PY, Schreiber MA; Trauma Outcomes Group; Holcomb JB, Wade CE, Brasel KJ, Vercruysse G, MacLeod J, Dutton RP, Hess JR, Duchesne JC, McSwain NE, Muskat P, Johannigamn J, Cryer HM, Tillou A, Cohen MJ, Pittet JF, Knudson P, De Moya MA, Schreiber MA, Tieu B, Brundage S, Napolitano LM, Brunsvold M, Sihler KC, Beilman G, Peitzman AB, Zenait MS, Sperry J, Alarcon L, Croce MA, Minei JP, Kozar R, Gonzalez EA, Stewart RM, Cohn SM, Mickalek JE, Bulger EM, Cotton BA, Nunez TC, Ivatury R, Meredith JW, Pomper P, Pomper GJ, Marin B. Rowell SE, et al. Among authors: pomper p. J Trauma. 2011 Aug;71(2 Suppl 3):S375-9. doi: 10.1097/TA.0b013e318227f1aa. J Trauma. 2011. PMID: 21814107